CA2995554A1 - Compose tetrahydrooxepinopyridine - Google Patents

Compose tetrahydrooxepinopyridine Download PDF

Info

Publication number
CA2995554A1
CA2995554A1 CA2995554A CA2995554A CA2995554A1 CA 2995554 A1 CA2995554 A1 CA 2995554A1 CA 2995554 A CA2995554 A CA 2995554A CA 2995554 A CA2995554 A CA 2995554A CA 2995554 A1 CA2995554 A1 CA 2995554A1
Authority
CA
Canada
Prior art keywords
compound
lower alkyl
ring
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2995554A
Other languages
English (en)
Other versions
CA2995554C (fr
Inventor
Yohei Koganemaru
Satoshi Miyamoto
Shinya Nagashima
Akio Kamikawa
Koichi Yonezawa
Yuka KOIZUMI
Satoshi Aoki
Takashi Ogiyama
Shimpei Kawakami
Shigeki Kunikawa
Ryo Sato
Junichi SHISHIKURA
Shuichirou Kakimoto
Hiroshi Yamada
Keisuke TAMAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CA2995554A1 publication Critical patent/CA2995554A1/fr
Application granted granted Critical
Publication of CA2995554C publication Critical patent/CA2995554C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

L'invention vise à fournir un composé qui présente un effet de modulation allostérique positif (effet PAM) pour un récepteur nicotinique à l'acétylcholine a7 (récepteur nACh a7). Les inventeurs ont réalisé la présente invention en effectuant des études sur les effets PAM pour un récepteur nACh a7 et en confirmant qu'un composé tétrahydrooxépinopyridine présente un effet PAM pour un récepteur nACh a7. Un composé tétrahydrooxépinopyridine selon la présente invention présente un effet PAM pour un récepteur nACh a7, et est prometteur en tant qu'agent prophylactique ou thérapeutique pour la démence, une déficience cognitive, la schizophrénie, la maladie d'Alzheimer, les déficits cognitifs associés à la schizophrénie (CIAS, pour "cognitive impairment associated with schizophrenia"), les symptômes négatifs de la schizophrénie, les maladies inflammatoires ou la douleur.
CA2995554A 2015-08-19 2016-08-18 Compose tetrahydrooxepinopyridine Active CA2995554C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-162320 2015-08-19
JP2015162320 2015-08-19
PCT/JP2016/074145 WO2017030171A1 (fr) 2015-08-19 2016-08-18 Composé tétrahydrooxépinopyridine

Publications (2)

Publication Number Publication Date
CA2995554A1 true CA2995554A1 (fr) 2017-02-23
CA2995554C CA2995554C (fr) 2023-06-27

Family

ID=58052257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2995554A Active CA2995554C (fr) 2015-08-19 2016-08-18 Compose tetrahydrooxepinopyridine

Country Status (21)

Country Link
US (1) US9670219B2 (fr)
EP (1) EP3345909B1 (fr)
JP (1) JP6787320B2 (fr)
KR (1) KR102614279B1 (fr)
CN (1) CN107922426B (fr)
AR (1) AR105738A1 (fr)
AU (1) AU2016308406A1 (fr)
CA (1) CA2995554C (fr)
CO (1) CO2018002472A2 (fr)
EA (1) EA034794B1 (fr)
ES (1) ES2812246T3 (fr)
HK (1) HK1251574A1 (fr)
IL (1) IL257450A (fr)
MX (1) MX2018002118A (fr)
PH (1) PH12018500297A1 (fr)
PL (1) PL3345909T3 (fr)
PT (1) PT3345909T (fr)
SG (1) SG11201801193QA (fr)
TW (1) TW201722962A (fr)
WO (1) WO2017030171A1 (fr)
ZA (1) ZA201801098B (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020672A1 (fr) * 2008-08-21 2010-02-25 Neurosearch A/S Nouveaux dérivés de phénylquinoléine-acide carboxylique-pyridine utiles comme modulateurs des récepteurs nicotiniques à l'acétylcholine
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
MY161236A (en) 2011-02-25 2017-04-14 Janssen Pharmaceutica Nv (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
AR086791A1 (es) * 2011-07-01 2014-01-22 Lundbeck & Co As H Moduladores alostericos positivos del receptor de acetilcolina nicotinico
US20130005743A1 (en) * 2011-07-01 2013-01-03 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
BR112018003171A2 (pt) 2018-09-25
MX2018002118A (es) 2018-06-18
US9670219B2 (en) 2017-06-06
WO2017030171A1 (fr) 2017-02-23
KR20180037983A (ko) 2018-04-13
ZA201801098B (en) 2019-04-24
CO2018002472A2 (es) 2018-05-31
AR105738A1 (es) 2017-11-01
JPWO2017030171A1 (ja) 2018-06-07
KR102614279B1 (ko) 2023-12-18
EA034794B1 (ru) 2020-03-23
HK1251574A1 (zh) 2019-02-01
IL257450A (en) 2018-04-30
ES2812246T3 (es) 2021-03-16
US20170050973A1 (en) 2017-02-23
EP3345909A1 (fr) 2018-07-11
TW201722962A (zh) 2017-07-01
PT3345909T (pt) 2020-07-29
PH12018500297A1 (en) 2018-08-13
JP6787320B2 (ja) 2020-11-18
CN107922426B (zh) 2021-03-26
EA201890514A1 (ru) 2018-07-31
CA2995554C (fr) 2023-06-27
CN107922426A (zh) 2018-04-17
EP3345909B1 (fr) 2020-06-17
AU2016308406A1 (en) 2018-03-08
EP3345909A4 (fr) 2019-04-10
PL3345909T3 (pl) 2020-10-19
SG11201801193QA (en) 2018-03-28

Similar Documents

Publication Publication Date Title
JP7307144B2 (ja) １，４－置換ピペリジン誘導体
TW202227433A (zh) 中環或大環之經苄基取代的雜環衍生物及相關用途
CA3047403A1 (fr) Modulateurs des recepteurs nmda et utilisations de ceux-ci
CN116583502A (zh) 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
EP1847535A1 (fr) Dérivé de 1-(pipéridin-4-yl)-1h-indole
EP4334323A1 (fr) Agonistes du récepteur de l'orexine et leurs utilisations
CN111655690A (zh) 吡唑并吡啶酮化合物
CA2800930C (fr) Nouveaux composes spiroheterocycliques en tant qu'antagonistes de mglu5
CA2995554C (fr) Compose tetrahydrooxepinopyridine
CA3152485A1 (fr) Derive d'azepane
CA2838036A1 (fr) Antibiotiques tricycliques
BR112018003171B1 (pt) Compostos de tetrahidrooxepinopiridina, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos
KR20230157439A (ko) 에스트로겐 수용체 조절제
TW202337460A (zh) 多醯胺類化合物、其製備方法及其醫藥用途
TW202304926A (zh) 二環性吡啶衍生物
CN117177977A (zh) 二环吡啶衍生物
CA3160368A1 (fr) Imidazolecarboxamide substitue utilise comme inhibiteurs de la tyrosine kinase de bruton
CA2972668A1 (fr) Derives d'heterocyclylalkyne et leur utilisation en tant que modulateurs des recepteurs mglur5

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329

EEER Examination request

Effective date: 20210329